

Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer

Yezi Zhu^{1,2}, Chengfei Liu¹, Nagalakshmi Nadiminty¹, Wei Lou¹, Ramakumar Tummala¹, Christopher P. Evans^{1,3}, and Allen C. Gao^{1,2,3}

Abstract

Docetaxel is the first-line standard treatment for castration-resistant prostate cancer. However, relapse eventually occurs due to the development of resistance to docetaxel. To unravel the mechanism of acquired docetaxel resistance, we established docetaxel-resistant prostate cancer cells, TaxR, from castration-resistant C4-2B prostate cancer cells. The IC₅₀ for docetaxel in TaxR cells was about 70-fold higher than parental C4-2B cells. Global gene expression analysis revealed alteration of expression of a total of 1,604 genes, with 52% being upregulated and 48% downregulated. *ABCB1*, which belongs to the ATP-binding cassette (ABC) transporter family, was identified among the top upregulated genes in TaxR cells. The role of *ABCB1* in the development of docetaxel resistance was examined. Knockdown of *ABCB1* expression by its specific shRNA or inhibitor resensitized docetaxel-resistant TaxR cells to docetaxel treatment by enhancing apoptotic cell death. Furthermore, we identified that apigenin, a natural product of the flavone family, inhibits *ABCB1* expression and resensitizes docetaxel-resistant prostate cancer cells to docetaxel treatment. Collectively, these results suggest that overexpression of *ABCB1* mediates acquired docetaxel resistance and targeting *ABCB1* expression could be a potential approach to resensitize docetaxel-resistant prostate cancer cells to docetaxel treatment. *Mol Cancer Ther*; 12(9); 1829–36. ©2013 AACR.

Introduction

Prostate cancer is the most common diagnosed cancer and second most frequent cause of cancer-related death among the men in the United States. Most of the patients with prostate cancer will initially respond to androgen deprivation therapy. However, almost all of them will relapse due to development of castration-resistant prostate cancer (CRPC; refs. 1, 2). Docetaxel is the first-line standard treatment for CRPC. Docetaxel is a cytotoxic antimicrotubule agent that binds to β -tubulin and prevents microtubule depolymerization, resulting in inhibition of mitotic cell division which leads to apoptotic cell death (3). However, relapse eventually occurs due to the development of resistance to docetaxel.

The molecular mechanisms of the acquired docetaxel resistance in prostate cancer cells are incompletely under-

stood. Studies to understand the underlying mechanisms of docetaxel resistance have uncovered several potential mechanisms of docetaxel resistance in prostate cancer (4, 5). Alterations of β -tubulin isotypes, especially the increase in isotypes III and IV, has been shown to be correlated with docetaxel resistance (6). Alterations of cell survival factors that inhibit chemotherapy-induced apoptotic cell death are associated with docetaxel resistance (7). Several different groups have reported that overexpression of Bcl-2 (8) and induction of clusterin by pAkt (9, 10) are related to docetaxel resistance in prostate cancer. Aberrant activation of central transcriptional factors such as NF- κ B also plays an important role in the development of resistance. Recent studies have shown that inhibition of NF- κ B resensitizes docetaxel-resistant PC-3 cells to taxane-induced apoptosis (11). Furthermore, reduced intracellular drug concentration through alteration of multidrug resistance (MDR) genes is another mechanism associated with the acquired resistance to chemotherapy (12).

To further understand the molecular mechanisms of the acquired docetaxel resistance and explore potential therapeutic strategies for docetaxel-resistant CRPC, we generated docetaxel-resistant prostate cancer cells from castration-resistant C4-2B prostate cancer cells. We identified *ABCB1* gene upregulation as a common mechanism involved in acquired docetaxel resistance. In addition, we show that apigenin, a natural product of the flavone

Authors' Affiliations: ¹Department of Urology, ²Graduate Program in Pharmacology and Toxicology, ³Comprehensive Cancer Center, University of California at Davis, Sacramento, California

Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (<http://mct.aacrjournals.org/>).

Corresponding Author: Allen C. Gao, Department of Urology, University of California Davis Medical Center, 4645 2nd Ave, Research III, Suite 1300, Sacramento, CA 95817. Phone: 916-734-8718; Fax: 916-734-8714; E-mail: acgao@ucdavis.edu

doi: 10.1158/1535-7163.MCT-13-0208

©2013 American Association for Cancer Research.

family, inhibits ABCB1 expression and resensitizes docetaxel-resistant prostate cancer cells to docetaxel treatment by enhancing apoptotic cell death.

Materials and Methods

Cell culture and reagents

DU145 cells were obtained from the American Type Culture Collection (ATCC). All experiments with cell line were conducted within 6 months of receipt from ATCC or resuscitation after cryopreservation. ATCC uses short tandem repeat (STR) profiling for testing and authentication of cell lines. C4-2B cells were kindly provided and authenticated by Dr. Leland Chung (Cedars-Sinai Medical Center, Los Angeles, CA). The cells were cultured in RPMI-1640 medium containing 10% complete FBS with 100 U/mL penicillin and 0.1 mg/mL streptomycin and maintained at 37°C in a humidified incubator with 5% CO₂. C4-2B cells were incubated with gradually increasing concentrations of docetaxel. Cells that survived the maximum concentration of docetaxel were stored for further analysis and referred to as TaxR cells. Parental C4-2B cells were passaged alongside the docetaxel-treated cells as an appropriate control. Docetaxel-resistant TaxR cells were maintained in 5 nmol/L docetaxel-containing medium. Docetaxel (CAS#114977-28-5) was purchased from TSZ CHEM. Apigenin (CAS#520-36-5) and Elacridar (CAS#143664-11-3) were purchased from Sigma-Aldrich. Antibodies against ABCB1, p53, phospho-p53, cleaved PARP, and GAPDH were obtained from Santa Cruz Biotechnologies.

Plasmids and cell transfection

Lentivector-based ABCB1 shRNA constructs were obtained from Open Biosystems. TaxR cells were transiently transfected with shRNA specific against ABCB1 or shGFP as vector control using Attractene transfection reagent (QIAGEN). TaxR shABCB1 and vector stable clones were selected with 2.0 µg/mL puromycin within 3 weeks after being transfected with ABCB1 shRNA or control vector and then maintained in culture medium containing 2.0 µg/mL puromycin.

Preparation of whole-cell extracts

Cells were harvested, washed with PBS twice, and lysed in high-salt buffer [10 mmol/L HEPES (pH 7.9), 0.25 mol/L NaCl, 0.1% NP-40] supplemented with protease inhibitors (Roche). Protein concentration was determined with Coomassie Plus Protein Assay Kit (Pierce).

Western blot analysis

Equal amounts of cell protein extracts were loaded on 8% or 10% SDS-PAGE, and proteins were transferred to nitrocellulose membranes. After blocking in 5% non-fat milk in 1 × PBS/0.1% Tween-20 at room temperature for 1 hour, membranes were washed three times with 1 × PBS/0.1% Tween-20. The membranes were incubated overnight with primary antibodies at 4°C. Proteins were visualized by enhanced chemiluminescence kit (Millipore)

after incubation with the appropriate horseradish peroxidase-conjugated secondary antibodies.

Real-time quantitative reverse transcription-PCR

Total RNA was extracted with TRIzol (Invitrogen) reagent. One microgram RNA was digested using RQ1 DNase (Promega). The resulting product was reverse transcribed with random primers using Im-Prom^{II} Reverse transcriptase (Promega). The newly synthesized cDNA was used to conduct real-time PCR. The reaction mixture contained 4 µL cDNA template and 0.5 µmol/L specific primers for ABCB1 (Forward: 5'-ATGCT CTGGC CTTCT GGATG GGA-3'; Reverse: 5'-ATGGC GATCC TCTGC TTCTG CCCAC-3'). GAPDH primers were used as an internal control. The expression levels of ABCB1 were normalized to GAPDH. The experiments were repeated three times with triplicates.

Cell growth assay

C4-2B and TaxR cells were seeded in 12-well plates at a density of 1 × 10⁵ cells per well. Cells were treated as indicated and total cell numbers were counted using Coulter cell counter.

Cell death ELISA

C4-2B and TaxR cells were seeded in 12-well plates at a density of 1 × 10⁵ cells per well and were treated as indicated. DNA fragmentation in the cytoplasmic fraction of cell lysates was determined using Cell Death Detection ELISA Kit (Roche) according to the manufacturer's instructions. Apoptotic cell death was measured at 405 nm.

Clonogenic ability assay

C4-2B and TaxR cells were treated with dimethyl sulfoxide or different doses of docetaxel for 6 hours. A total of 1 × 10³ cells were then plated in 100 mm dish for 14 days. The cells were fixed with 4% formaldehyde for 10 minutes and then stained with 0.5% crystal violet for 30 minutes, and the numbers of colonies were counted.

cDNA microarray analysis

Twenty-four hours after plating of 1 × 10⁵ C4-2B and TaxR cells, total RNA was isolated using TRIzol Reagent (Invitrogen) and purified with Eppendorf phase-lock-gel tube. RNA quality of all samples was tested by RNA electrophoresis to ensure RNA integrity. Samples were analyzed by the Genomics Shared Resource (UC Davis Medical Center, Sacramento, CA) using the Affymetrix Human Gene 1.0 ST array. Microarray data have been deposited at GEO with the accession number GSE47040.

Statistical analyses

All data are presented as means ± SD. Differences between multiple groups were determined using one-way ANOVA followed by the Scheffe procedure for comparison of means. *P* < 0.05 was considered significant.

Results

Development and characterization of a docetaxel-resistant prostate cancer cell line

We previously showed that docetaxel induces p53 phosphorylation in docetaxel-sensitive LNCaP and C4-2B cells, but fails to induce p53 phosphorylation in docetaxel-resistant DU145 cells (13). To further confirm these findings, we established a docetaxel-resistant cell line, TaxR, from C4-2B cells by culturing C4-2B cells in docetaxel in a dose-escalation manner (starting from 0.1 nmol/L). After 9-month selection, cells were able to divide freely in 5 nmol/L docetaxel. To test the effect of docetaxel treatment on parental C4-2B and TaxR cell viability, cell growth assay was conducted. Both cell lines were treated with increasing concentrations of docetaxel for 24 hours. As shown in Fig. 1A, C4-2B cells are sensitive to docetaxel treatment with an IC_{50} of 2 nmol/L, whereas TaxR cells are much more resistant to docetaxel with an IC_{50} of 140 nmol/L, about 70-fold increase over parental C4-2B cells. To determine whether docetaxel induces p53 phosphorylation in TaxR cells, TaxR cells and parental C4-2B cells were treated with increasing doses of docetaxel and cell lysates were isolated for Western blot analysis. As shown in Fig. 1B, docetaxel treatment induces p53 phosphorylation in C4-2B cells, but not in TaxR cells, consistent with previous report that p53 phosphorylation is associated with docetaxel sensitivity in prostate cancer cells.

The effect of docetaxel on clonogenic ability of both C4-2B and TaxR cells was determined. The clonogenic ability of TaxR cells was significantly higher than that of parental

C4-2B cells in response to docetaxel treatment (Fig. 2A and B). To test the ability of docetaxel to induce apoptotic cell death in prostate cancer cells, C4-2B and TaxR cells exposed to 5 nmol/L docetaxel for 48 hours were examined by apoptosis-specific ELISA assay as described in Materials and Methods. Docetaxel at 5 nmol/L concentration induced significant apoptotic cell death in parental C4-2B cells but had little effect on TaxR cells (Fig. 2C and D).

ABCB1 is overexpressed in TaxR cells

Several mechanisms have been proposed for docetaxel resistance in prostate cancer, such as alteration in β -tubulin isoforms, reduced intracellular concentration of drug through alteration of MDR genes and alteration of cell survival factors and transcription factors (6–10). To identify genes responsible for docetaxel resistance in TaxR cells, global gene expression analysis by cDNA microarrays (~28,000 genes) was conducted using mRNA from parental C4-2B and TaxR cells. Gene expression analysis revealed that a total of 1,604 genes were altered in TaxR cells with 52% being upregulated and 48% downregulated. The 1,604 genes that are altered in TaxR cells were compared with the public database generated from docetaxel-resistant DU145DR and Rv1DR cells (14). Only 9 genes altered by docetaxel were found to be overlapping in the three-gene data sets (Fig. 3A). *ABCB1*, which belongs to the ATP-binding cassette (ABC) transporter family, was identified among the top upregulated genes in TaxR cells, which is also among the 9 overlapped genes in the three-gene datasets. To verify microarray analysis, total RNAs were isolated from C4-2B and TaxR cells, and *ABCB1* mRNA level was measured using specific primers by qRT-PCR. As shown in Fig. 3B, *ABCB1* mRNA was highly expressed in TaxR cells but was not detectable in parental C4-2B. *ABCB1* protein expression was analyzed by Western blotting in whole-cell extracts of parental C4-2B and TaxR cells. Figure 3C showed that *ABCB1* was overexpressed in TaxR cells but was not detectable in parental C4-2B cells. These data suggested that *ABCB1* is overexpressed in docetaxel-resistant TaxR cells at both mRNA and protein levels.

Downregulation of ABCB1 reverses docetaxel resistance

Having identified that *ABCB1* is overexpressed in docetaxel-resistant TaxR cells, we next tested whether overexpression of *ABCB1* leads to docetaxel resistance in TaxR cells. As shown in Fig. 4A, inhibition of *ABCB1* expression by *ABCB1* shRNA resensitized TaxR cells to docetaxel treatment. Figure 4B confirmed that *ABCB1* protein expression was knocked down by *ABCB1* shRNA. This observation was confirmed in another docetaxel-resistant DU145-R cell line, in which knockdown of *ABCB1* expression by *ABCB1* shRNA reversed docetaxel resistance (Supplementary Fig. S1). To further confirm that downregulation of *ABCB1* could restore sensitivity to docetaxel, we established stable transfectant TaxR cells expressing




Figure 1. TaxR cells are more resistant to docetaxel than parental C4-2B cells. Parental C4-2B cells and TaxR cells were treated with indicated concentrations of docetaxel in media containing complete FBS for 24 hours. A, cell growth assay. Results are expressed as the percentage of treated cells relative to untreated cells. B, docetaxel induces phospho-p53 expression in C4-2B cells but not in TaxR cells. Whole-cell lysates were collected and subjected to Western blot analysis using the indicated antibodies.




Figure 2. Effects of docetaxel on clonogenic ability and apoptotic cell death in TaxR cells and C4-2B cells. A, effects of docetaxel on clonogenic ability. C4-2B and TaxR cells were treated with docetaxel as indicated. After 6 hours of treatment, 1,000 cells were plated in 100 mm dish in media containing complete FBS. Visible clones were formed after 3 weeks. B, numbers of colonies were counted. C, effects of docetaxel on apoptotic cell death. C4-2B and TaxR cells were treated with 5 nmol/L docetaxel for 48 hours. Mono- and oligonucleosomes of cytoplasmic fraction were analyzed by cell death detection ELISA. D, photographs of C4-2B and TaxR cells treated with 5 nmol/L docetaxel were taken.

ABCB1 shRNA. Two independent clones (clones No. 2 and No. 30) with ABCB1 downregulation were selected for further analysis (Fig. 4C). As shown in Fig. 4D, downregulation of ABCB1 increased the sensitivity of TaxR cells to docetaxel treatment. The IC_{50} of docetaxel was reduced from 140 nmol/L (vector control of parental TaxR cells) to about 20 nmol/L in both clone No. 2 and No. 30. Furthermore, we used ABCB1 inhibitor, Elacridar, to test whether inhibition of ABCB1 activity reverses docetaxel resistance in TaxR cells. As shown in Fig. 4E, treatment with 0.5 μ mol/L Elacridar for 24 hours resensitized TaxR cells to

docetaxel treatment, leading to both growth inhibition (Fig. 4E) and induction of apoptosis (Fig. 4F). Collectively, these data suggested that while ABCB1 overexpression enhances docetaxel resistance, inhibition of ABCB1 expression resensitizes prostate cancer cells to docetaxel treatment.

Apigenin downregulates ABCB1 expression and reverses docetaxel resistance

As downregulation of ABCB1 reverses docetaxel resistance, we attempted to search for agents that can inhibit




Figure 3. ABCB1 is overexpressed in TaxR cells. A, analysis of gene expression data sets. Genes with at least 1.2-fold increase (↑) and decrease (↓) in expression on comparison of parental C4-2B and TAXR cells are listed. B, real-time PCR analysis of ABCB1 mRNA in C4-2B and TaxR cells. C, ABCB1 protein expression. ABCB1 expression was determined by Western blot analysis using antibody specific against ABCB1.




Figure 4. Downregulation of ABCB1 expression resensitizes TAXR cells to docetaxel treatment. **A**, transient downregulation of ABCB1 expression resensitized TaxR cells to docetaxel treatment. After 48 hours of transfection with 2 μ g shABCB1 or control, TaxR cells were treated with vehicle or 50 nmol/L docetaxel for 48 hours and cell numbers were counted. **B**, efficient downregulation of ABCB1 protein levels was shown by Western blot analysis. **C**, stable clones (clone #2 and #30) with downregulation of ABCB1 expression were generated. TaxR cells were stably transfected with shRNA of ABCB1 or vector control. Downregulation of ABCB1 was verified in clone No. 2 and No. 30 at both mRNA and protein levels. **D**, stable downregulation of ABCB1 expression resensitized TaxR cells to docetaxel treatment. Parental C4-2B, TaxR-ctrl cells, and clones No. 2, 30 cells were treated with indicated concentrations of docetaxel for 48 hours and cell numbers were counted. **E**, downregulation of ABCB1 expression by elacridar resensitized TaxR cells to docetaxel treatment. C4-2B and TaxR cells were treated with docetaxel (25 nmol/L) alone or in the presence of the ABCB1 inhibitor Elacridar (0.5 μ mol/L). Cell numbers were counted after 24 hours of exposure (left); growth media were collected and assayed for apoptosis by cell death ELISA (right). Bottom, ABCB1 protein levels in TaxR cells treated as indicated. *, statistically significant differences between groups ($P < 0.05$).

ABCB1 expression and therefore increase docetaxel sensitivity. Apigenin (4',5,7-trihydroxyflavone), a natural product belonging to the flavone family, has the ability to modulate multidrug resistance genes and induce apoptosis in prostate cancer cells (15). We tested whether apigenin inhibits ABCB1 expression in docetaxel-resistant TaxR cells. TaxR cells were treated with increasing concentrations of apigenin. Total proteins were extracted after 48 hours of exposure and assessed by Western blot analysis. As shown in Fig. 5A, apigenin downregulates ABCB1 protein expression in a dose-dependent manner. To examine whether apigenin could reverse docetaxel

resistance in TaxR cells, TaxR cells were treated with 20 nmol/L docetaxel alone or in the combination with 10 μ mol/L apigenin. As shown in Fig. 5B, docetaxel alone at the concentration of 10 μ mol/L reduced TaxR cell growth by about 10% to 20%, whereas the combination of 20 nmol/L docetaxel and 10 μ mol/L apigenin reduced growth of TaxR cells by about 50%. Cell death ELISA showed that the combination of apigenin and docetaxel induced apoptotic cell death (Fig. 5C and D). The combination treatment also induced cleavage of PARP, a marker of apoptotic cell death, as shown by Western blot analysis




Figure 5. Apigenin downregulates ABCB1 expression and suppresses acquired docetaxel resistance. **A**, apigenin inhibits ABCB1 expression. TaxR cells were treated with different doses of apigenin as indicated. After 48 hours of exposure, whole-cell lysates were collected. ABCB1 expression levels were analyzed by Western blot using specific antibody. **B**, apigenin resensitizes TaxR cells to docetaxel treatment. TaxR cells were treated with either 10 μmol/L apigenin alone or with 20 nmol/L docetaxel. After 48 hours of treatment, cell numbers were counted. **C**, mono- and oligonucleosomes of cytosolic fractions were assessed for cell death detection ELISA (left) and whole-cell extracts were subjected to Western blot analysis using specific antibodies as indicated (right). **D**, photographs of TaxR cells treated as indicated were taken.

(Fig. 5C). These results show that apigenin restores docetaxel sensitivity of TaxR cells, suggesting that treatment with a combination of apigenin and docetaxel could be a potential strategy to overcome docetaxel resistance in castration-resistant prostate cancer.


Discussion

Docetaxel is used as first-line treatment for patients with castration-resistant prostate cancer that failed bicalutamide therapy. However, relapse eventually occurs due to the development of resistance to docetaxel. In this study, we generated a docetaxel-resistant prostate cancer cell subline, TaxR, from parental castration-resistant C4-2B cells. We identified *ABCB1*, which belongs to the ATP-binding cassette (ABC) transporter family, as the top upregulated gene in TaxR cells through global gene expression analysis and expression validation. Knock-down of ABCB1 expression by its specific shRNA or the inhibitor, Elacridar, resensitized docetaxel-resistant TaxR cells to docetaxel. In addition, we show that apigenin, a natural product of the flavone family, inhibits ABCB1 expression and resensitizes docetaxel-resistant TaxR cells to docetaxel treatment.

Several docetaxel-resistant prostate cancer cell lines have been generated including PC-3, DU145, and CWR22Rv1 (11, 14, 16). Using these docetaxel-resistant cell models, several genes have been identified to be

associated with docetaxel resistance. Overexpression of Notch and Hedgehog signaling has been found to be linked to docetaxel resistance in DU145 and CWR22Rv1 cells (14). Downregulation of CDH1 and IFIH1 has been identified in docetaxel-resistant PC-3 and DU145 cells and verified in prostate tumors from docetaxel-resistant patients (16). We generated the TaxR docetaxel-resistant cell line from C4-2B cells cultured in media containing docetaxel for a long period of time. The cells are about 70-fold more resistant to docetaxel compared with parental C4-2B cells, with an IC_{50} of 140 nmol/L docetaxel. Interestingly, in addition to docetaxel, TaxR cells are resistant to paclitaxel, but not to doxorubicin (Fig. 6). This may be due to different mechanisms of action between taxane (docetaxel and paclitaxel) family (microtubule stabilization) and doxorubicin (DNA intercalation and topoisomerase II inhibition). Using global gene expression analysis, we identified ABCB1 as a top upregulated gene in TaxR cells versus parental C4-2B cells. Data analysis of public data bases generated from docetaxel-resistant DU145DR and Rv1DR cells showed that ABCB1 is also overexpressed in both DU145DR and Rv1DR cells (14), suggesting that overexpression of ABCB1 is a common mechanism involved in acquired docetaxel-resistant prostate cancer. Functional validation studies showed that inhibition of ABCB1 expression resensitized TaxR cells to docetaxel.

Figure 6. Effects of paclitaxel and doxorubicin on TaxR cells. C4-2B and TaxR cells were treated with increasing doses of paclitaxel or doxorubicin as indicated for 48 hours. Numbers for cells untreated were expressed as 100% and numbers for cells treated with indicated concentrations of drugs were expressed as % relative to untreated group. A, paclitaxel; B, doxorubicin.



The results show that resensitization of TaxR cells to docetaxel treatment by downregulation of ABCB1 may have potential clinical implications. ABCB1 (P-glycoprotein, or MDR1) belongs to the ATP-binding cassette (ABC) transporters that use the energy of ATP hydrolysis to transport substrates including alkaloids, anthracyclines and taxanes across cell membranes and diminish efficacy of the drug (17). Early studies showed that increased expression of ABCB1 confers resistance to chemotherapeutic agents including docetaxel (11, 18, 19). In addition, ABCB1 expression is directly correlated with prostate tumor grade and stage (20). It is possible that while patients respond initially to docetaxel treatment, ABCB1 expression is induced by docetaxel and subsequently transports docetaxel across cell membranes, thus diminishing efficacy and resulting in development of resistance. Together with the results showing that ABCB1 is overexpressed in docetaxel-resistant TaxR cells and downregulation of ABCB1 expression increases docetaxel sensitivity, induction of expression of ABCB1 by docetaxel may be one of the key mechanisms that are responsible for the acquired docetaxel resistance, and targeting ABCB1 expression could be a valid strategy to augment docetaxel efficacy and enhance the duration of treatment.

Overcoming docetaxel resistance presents a huge challenge to the treatment and management of docetaxel-resistant CRPC. On the basis of our finding that downregulation of ABCB1 resensitizes docetaxel-resistant prostate cancer to docetaxel treatment, we attempted to identify inhibitors of ABCB1 and tested their ability to overcome docetaxel resistance. Toward this goal, we have identified apigenin, a natural product belonging to the flavone family, as an inhibitor of ABCB1. Apigenin, 4',5,7-trihydroxyflavone, has gained particular interest in recent years because of its low cytotoxicity and significant effects on cancer cells versus normal cells (21, 22). The antitumor effects of apigenin have been identified in a wide variety of malignant cells including prostate (15, 23, 24), melanoma (25, 26), breast (27, 28), leukemia (29), lung (30), and colon (31). Apigenin acts on a broad range of molecular signaling including suppression of the PI3K-Akt pathway in breast cancer (27, 28), induction of G₂-M arrest by

modulating cyclin-CDK regulators and MAPK activation (32), and alteration of the expression levels of proapoptotic factors like Bax/Bcl2, which leads to caspase activation and PARP cleavage (23). More recently, apigenin has been shown to be able to sensitize cancer cells to taxane-induced apoptotic death by promoting the accumulation of ROS in a caspase-2-dependent manner (33). Our findings showing that apigenin inhibits ABCB1 expression and overcomes docetaxel resistance provide additional evidence that apigenin may play a role in the management of CRPC after failure of docetaxel therapy.

Collectively, these results suggest that overexpression of ABCB1 may be a potential mechanism that is responsible for docetaxel resistance in prostate cancer and that targeting ABCB1 expression may be an attractive approach to resensitize docetaxel-resistant prostate cancer cells to docetaxel.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: Y. Zhu, C.P. Evans, A.C. Gao
Development of methodology: Y. Zhu, R. Tummala, C.P. Evans, A.C. Gao
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y. Zhu, C. Liu, A.C. Gao
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y. Zhu, C. Liu, C.P. Evans, A.C. Gao
Writing, review, and/or revision of the manuscript: Y. Zhu, N. Nadimity, R. Tummala, C.P. Evans, A.C. Gao
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Y. Zhu, C. Liu, W. Lou, A.C. Gao
Study supervision: Y. Zhu, C.P. Evans, A.C. Gao

Grant Support

This work is supported in part by grants NIH/NCI CA140468, CA118887, DOD PCRP PC080538 (to A.C. Gao), U.S. Department of Veterans Affairs, Office of Research and Development VA Merits I01 BX000526 (to A.C. Gao), and by resources from the VA Northern California Health Care System (Sacramento, CA). The UC Davis Comprehensive Cancer Center Genomics Shared Resource is supported by Cancer Center Support Grant P30 CA93373-01 from the NCI.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 20, 2013; revised May 31, 2013; accepted June 17, 2013; published OnlineFirst July 16, 2013.

References

- Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. *Nat Clin Pract Urol* 2009; 6:76–85.
- Kim SJ, Kim SI. Current treatment strategies for castration-resistant prostate cancer. *Korean J Urol* 2011;52:157–65.
- Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. *Nat Rev Cancer* 2004;4:253–65.
- Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. *Nature* 2007;446:749–57.
- Antonarakis ES, Armstrong AJ. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. *Prostate Cancer Prostatic Dis* 2011;14:192–205.
- Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. *ChemMedChem* 2007;2:920–42.
- Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. *Nat Rev Clin Oncol* 2011;8: 12–23.
- Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda Y, Shigeno K, et al. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. *Clin Cancer Res* 2006;12:6116–24.
- Zhong B, Sallman DA, Gilvary DL, Pernazza D, Sahakian E, Fritz D, et al. Induction of clusterin by AKT-Role in cytoprotection against docetaxel in prostate tumor cells. *Mol Cancer Ther* 2010;9:1831–41.
- Kosaka T, Miyajima A, Shirotake S, Suzuki E, Kikuchi E, Oya M. Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer. *J Urol* 2011;185: 2376–81.
- O'Neill AJ, Pencipe M, Dowling C, Fan Y, Mulrane L, Gallagher W, et al. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. *Mol Cancer* 2011;10:126.
- Gottesman MM, Fojo T, Bates S. Multidrug resistance in cancer: role of ATP-dependent transporters. *Nat Rev Cancer* 2002;2:48–58.
- Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, et al. Functional p53 determines docetaxel sensitivity in prostate cancer cells. *Prostate* 2013;73:418–27.
- Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. *Cancer Cell* 2012;22: 373–88.
- Shukla S, Gupta S. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. *Clin Cancer Res* 2004;10:3169–78.
- Marin-Aguilera M, Codony-Servat J, Kalko SG, Fernandez PL, Bermudo R, Buxo E, et al. Identification of docetaxel resistance genes in castration-resistant prostate cancer. *Mol Cancer Ther* 2012;11: 329–39.
- Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. *Pharmacogenomics* 2008;9:105–27.
- Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman M. Targeting multidrug resistance in cancer. *Nat Rev Drug Discov* 2006; 5:219–34.
- Sanchez C, Mercado A, Contreras HR, Mendoza P, Cabezas J, Acevedo C, et al. Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins. *Prostate* 2011;71:1810–7.
- Bhargal G, Halford S, Wang J, Roylance R, Shah R, Waxman J. Expression of the multidrug resistance gene in human prostate cancer. *Urol Oncol* 2000;5:118–21.
- Gupta S, Afaq F, Mukhtar H. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. *Biochem Biophys Res Commun* 2001;287:914–20.
- Shukla S, Gupta S. Apigenin: a promising molecule for cancer prevention. *Pharm Res* 2010;27:962–78.
- Gupta S, Afaq F, Mukhtar H. Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. *Oncogene* 2002;21: 3727–38.
- Shukla S, Gupta S. Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. *Mol Carcinog* 2004;39:114–26.
- Iwashita K, Kobori M, Yamaki K, Tsushida T. Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells. *Biosci Biotechnol Biochem* 2000;64:1813–20.
- Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M, et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. *Int J Cancer* 2000;87:595–600.
- Way TD, Kao MC, Lin JK. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. *J Biol Chem* 2004;279:4479–89.
- Long X, Fan M, Bigsby RM, Nephew KP. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms. *Mol Cancer Ther* 2008;7:2096–108.
- Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. *Eur J Cancer* 1999;35:1517–25.
- Li ZD, Liu LZ, Shi X, Fang J, Jiang BH. Benzo[a]pyrene-3,6-dione inhibited VEGF expression through inducing HIF-1alpha degradation. *Biochem Biophys Res Commun* 2007;357:517–23.
- Wang W, Heideman L, Chung CS, Pelling JC, Koehler KJ, Birt DF. Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. *Mol Carcinog* 2000;28:102–10.
- Yin F, Giuliano AE, Law RE, Van Herle AJ. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. *Anticancer Res* 2001;21:413–20.
- Xu Y, Xin Y, Diao Y, Lu C, Fu J, Luo L, et al. Synergistic effects of apigenin and paclitaxel on apoptosis of cancer cells. *PLoS ONE* 2011;6:e29169.